LONDON (Reuters) - Costly new antipsychotic drugs are not significantly better than cheaper older ones at treating a first episode of schizophrenia, Dutch researchers said on Friday. The finding adds to controversy about the benefits of second-generation products like AstraZeneca Plc’s Seroquel and Eli Lilly and Co’s Zyprexa, which were introduced in the 1990s and are now multibillion-dollar sellers.
